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Summary Isoforms of the transmembrane glycoprotein CD44 have been implicated in tumour cell adhesion, tumour differentiation and
metastatic spread in various human malignancies. We investigated the expression of CD44 isoforms containing variant exons v3, v5, v6 and
v7-8 in 156 human endometrium cancer specimens by means of immunohistochemistry. CD44 isoforms CD44v3, CD44v5, CD44v6 and
CD44v7-8 were detected in 26% (41 out of 156), 31% (48 out of 156), 22% (35 out of 156) and 15% (23 out of 156) of the tumour samples
respectively. The expression of CD44 isoforms CD44v3, CD44v5 and CD44v7-8 showed no prognostic impact. In the univariateanalysis, the
expression of CD44v6 showed an association with shortened overall survival (log-rank test, P= 0.06). Multivariate analysis correcting forthe
confounding variable histological grading revealed CD44v6 not to be a prognostic factor in endometrial cancer (log-rank test, P = 0.06).
Comparing the expression of CD44 isoforms CD44v3, CD44v5, CD44v6 and CD44v7-8 in 45 specimens of normal endometrial tissue, we
found an up-regulation of all investigated CD44 isoforms in the secretory phase compared with the proliferative phase of the menstrual cycle.
Our data indicate that the expression of CD44 isoforms, while obviously playing a role in the functional changes of normal endometrium, is not
an adverse predictive factor in endometrial cancer.
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Endometrial cancer is the most common neoplasm of the female
genital tract. In recent years the incidence of endometrial cancer
has shown a steady increase (Gallup et al, 1984). A closer follow-
up ofpost-menstrual bleedings and a greater awareness ofwomen
towards the disease has led to an increasing number of women
diagnosed with early-stage endometrial cancer. New prognostic
indicators could be helpful in defining high-risk collectives within
this group ofpatients who generally enjoy an excellent prognosis.
The transmembrane receptor protein CD44 belongs to the
family ofadhesion molecules, which are involved in cell-cell and
cell-matrix interactions. CD44 mediates lymphocyte functions,
such as cell activation, motility, division, adhesion to extracellular
matrix and adhesion to stromal cells (Stamenkovic et al, 1991).
CD44 proteins are encoded by a gene located on chromosome
11. By modifications of pre-messenger RNA, i.e. alternative
splicing, numerous isoforms of the CD44 protein are produced
(CD44 isoforms CD44vl-CD44v1O) (Tanabe et al, 1994).
Expression of CD44 isoforms has been shown to be associated
with metastasis and poor prognosis in colorectal cancer, gastro-
intestinal lymphoma, non-Hodgkin's lymphoma, thyroid, cervical
and vulvar cancer (Jalkanen et al, 1991; Joensuu et al, 1993a;
Wielenga et al, 1993; Figge et al, 1994; Kainz et al, 1995; Tempfer
et al, 1996).
The CD44 standard molecule as well as CD44 isoforms, e.g.
CD44v6, have been shown to be expressed in normal endometrial
tissue. Behzad and colleagues have shown that the expression of
CD44 isoforms is associated with different tissue compartments of
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the endometrium (Behzad et al, 1994). The expression pattern of
CD44 depends on the menstrual cycle and is characterized by a
sharp up-regulation ofCD44 standard and CD44 variant isoforms
in the secretory phase. It has been suggested that CD44 may play a
functional role in normal endometrium, possibly being involved in
the implantation of blastocysts in secretory transformed endome-
tria (Yaegashi et al, 1995). Fujita and colleagues have shown that
CD44 isoforms are also expressed in endometrial carcinomas
(Fujita et al, 1994).
The aim of our study was to evaluate whether CD44 isoform
expression is a prognostic factor in endometrial cancer. CD44
isoformexpression could eventually be used as a means toidentify
patients who would profit from adjuvant therapy. To address these
questions, we examined the expression of CD44 isoforms
CD44v3, CD44v5, CD44v6 and CD44v7-8 in tumour samples of
156 patients with surgically treated endometrial cancer.
MATERIALS AND METHODS
We investigated a randomly selected sample of 156 paraffin-
embedded tumour specimens of surgically treated endometrial
cancer. The median age ofthe patients was 59 years (range 48-71
years). Patients operated upon from 1976 to 1991 underwent
hysterectomy and bilateral salpingo-oophorectomy. Because ofthe
study period, lymphadenectomy, as recommended by Malviya and
colleagues and Morrow and colleagues, was not performed on a
regular basis (Malviya et al, 1989; Morrow et al, 1991). Therefore
the lymph node status was not included in further analysis. The
median follow-up time was 82.6 months (range 39-110 months).
During the observation period, 23 patients showed recurrence of
disease. Nineteen patients died ofthe disease.
Endometrioid-type adenocarcinomas, adenosquamous carci-
nomas, clear cell carcinomas and undifferentiated adenocarci-
nomas were found in 113, 25, eight and ten cases respectively. All
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Table 1 Multivariate analysis of prognostic factors for overall survival
Prognostic factors P Relative 95% Confidence
risk interval
Histological grading
(Gl + G2 vs G3) 0.13 2.4 0.75-7.7
CD44v3 0.26 1.8 0.62-5.6
CD44v5 0.29 1.7 0.61-5.1
CD44v6 0.06 2.8 0.97-8.1
CD44v7-8 0.3 1.8 0.52-6.6
1.0 -
c 0.5 -
0 .O
0 0~
0 -
No CD44v6 expression
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Figure 1 Kaplan-Meier analysis of overall survival in patients suffering from
tumours with or without expression of CD44v6
cases were reviewed by an experienced pathologist with regard
to tumour stage and histological grading. Histological staging
was performed according to the current UICC classification
(Hermanek et al, 1992).
We also investigated 45 specimens of normal endometrial
tissue, 19 of them being in the proliferative phase and 26 in the
secretory phase of the menstrual cycle. The endometrial speci-
mens were taken from randomly selected tissue samples of
patients with benign conditions, e.g. myoma uteri.
Immunohistochemistry
Immunohistochemical procedures were performed as described
previously (Kainz et al, 1995). We interpreted widespread staining
as positive, focal staining (< 10% ofthe tumour cells) as negative.
Statistics
Chi-square test was used when appropriate. Survival probabilities
were calculated by the product limit method of Kaplan and Meier.
Differences between groups were tested using the log-rank test.
Cox proportional hazards regression model was used to assess the
independence of different prognostic factors. In multivariate
analysis, the different CD44 isoforms were tested for their
independent effect, adjusted for histological grading. Kendall-Tau
correlation coefficient was used to assess the correlation between
the expression of different CD44 isoforms. The significance level
assumed was alpha = 0.05.
RESULTS
CD44 isoforms CD44v3, CD44v5, CD44v6 and CD44v7-8 were
detected by immunohistochemistry in 26% (41 out of 156), 31%
(48 out of 156), 22% (35 out of 156) and 15% (23 out of 156) of
the tumour samples respectively; staining of less than 10% of the
tumourcells, which was rated as negative, was found in three, one,
one and zero cases respectively. Staining was restricted to glan-
dular cells. Tumour stroma was negative. The staining pattern was
found to be membrane bound, although in 20% of cases we also
observed granular staining components additional to the
membrane staining.
In 19 specimens of normal endometrial tissue of the prolifera-
tive phase of the menstrual cycle, CD44 isoforms CD44v3,
CD44vS, CD44v6 and CD44v7-8 were detected by immunohisto-
chemistry in one, three, zero and zero cases respectively. In 26
specimens of the secretory phase, CD44 isoforms CD44v3,
CD44v5, CD44v6 and CD44v7-8 were detected by immunohisto-
chemistry in 12, 19, eight and three cases respectively.
We examined the correlation between the expression ofCD44v3,
CD44v5, CD44v6 and CD44v7-8 and tumour stage, histological
grade, depth of myometrial infiltration and histological type. No
statistically significant correlations between these histopathological
parameters and the expression of CD44 isoforms was found.
Correlation coefficients for CD44v3/CD44v5, CD44v3/CD44v6,
CD44v3/CD44v7-8, CD44vS/CD44v6, CD44vS/CD44v7-8, and
CD44v6/CD44v7-8 were 0.23, 0.06, 0.37, 0.28, 0.34 and 0.21
respectively.
In the univariate analysis, the expression of CD44v3 (log-rank
test, P = 0.5), CD44v5 (log-rank test, P = 0.3) and CD44v7-8 (log-
rank test, P = 0.4) did not predict patient survival. Although the
expression of CD44v6 showed an association with shortened
overall survival (Figure 1), univariate analysis demonstrated that
this association was not statistically significant (log-rank test,
P = 0.06). Multivariate analysis correcting for the confounding
variable histological grading revealed CD44v6 not to be an
independent prognostic factor of overall survival (log-rank test,
P = 0.06, Table 1).
DISCUSSION
The expression of CD44 variant isoforms has been shown to be
associated with poor prognosis in a wide variety of human malig-
nancies, e.g. colorectal cancer, gastrointestinal lymphoma, non-
Hodgkin's lymphoma and cervical cancer (Jalkanen et al, 1991;
Joensuu et al, 1993a; Wielenga et al, 1993; Kainz et al, 1995).
However, CD44 has been shown to be down-regulated aftermalig-
nant transformation ofcertain cell types (Salmi et al, 1993) and the
prognostic value of CD44 isoform expression in ovarian and
breast cancers is discussed controversially (Joensuu et al, 1993b;
Kaufmann et al, 1995; Sliutz et al, 1995; Uhl-Steidl et al, 1995). It
may be speculated that the role of CD44 as a metastasis mediator
in these hormonally regulated malignancies is impaired by
hormonal interference with biological properties ofCD44. On the
other hand, CD44 expression is not correlated with hormonal
phenotypes in neuroendocrine tumours and has been shown to be
independent of oestrogen and progesterone receptor status in
breast cancer (Komminoth et al, 1996; Charpin et al, 1997).
In the present study, we found CD44 isoforms CD44v3,
CD44v5, CD44v6 and CD44v7-8 to be expressed in endometrial
cancer in relatively low amounts, ranging from 13% to 29%. The
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immunohistochemical approach of detecting CD44 overexpres-
sion must be viewed with care because of possible modifications
of cell surface expression as a result of embedding procedures.
However, in recent studies, an excellent correlation between
the detection of CD44 isoforms by immunohistochemistry and
reverse transcription polymerase chain reaction has been reported
(Dall et al, 1995).
Yaegashi and colleagues have shown that the expression of
CD44 isoforms in normal endometrial tissue is restricted to the
secretory phase ofthe menstrual cycle (Yaegashi et al, 1995). This
is confirmed by our results pointing to a functional role ofCD44 in
normal endometrial tissue.
A review of the literature shows that no data concerning the
prognostic value of CD44 isoform expression in endometrial
cancer have been reported. In the present study, we found that the
expression ofCD44 isoforms CD44v3, CD44v5 and CD44v7-8 is
not associated with established prognostic parameters and is not
predictive ofthe patient's outcome. This is in accordance with find-
ings reported by Fujita and colleagues, who found no correlation
between CD44 isoform expression and clinicopathological risk
factors in a series of47 endometrial carcinomas (Fujita et al, 1994).
We found CD44v6 to be expressed in 22% ofendometrial carci-
nomas. Although the expression ofCD44v6 showed an association
with shortened overall survival, univariate analysis (log-rank test,
P = 0.06) and multivariate analysis correcting for the confounding
variable histological grading (log-rank test, P = 0.06) revealed
CD44v6 not to be a prognostic factor in endometrial cancer.
In summary, our data indicate that the expression of CD44
isoforms, while obviously playing a role in the functional changes
of normal endometrium, is not an adverse predictive factor in
endometrial cancer.
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